Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
SCYNEXIS Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SCYX
Nasdaq
2834
https://www.scynexis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for SCYNEXIS Inc
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
- Apr 30th, 2024 8:05 pm
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
- Apr 9th, 2024 8:05 pm
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
- Mar 28th, 2024 8:01 pm
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
- Jan 30th, 2024 9:05 pm
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
- Jan 29th, 2024 10:15 pm
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
- Jan 5th, 2024 1:30 pm
Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago
- Nov 30th, 2023 2:58 pm
11 Cheapest Stocks With Biggest Upside
- Nov 27th, 2023 3:33 pm
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 10:17 pm
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
- Oct 24th, 2023 12:00 pm
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
- Oct 16th, 2023 12:00 pm
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
- Sep 28th, 2023 12:31 am
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
- Sep 27th, 2023 11:49 am
UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk
- Sep 25th, 2023 12:55 pm
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?
- Sep 20th, 2023 8:00 am
SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?
- Sep 12th, 2023 11:45 am
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
- Sep 4th, 2023 5:31 pm
Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now
- Aug 29th, 2023 2:17 am
SCYNEXIS to Participate in September Investor Conferences
- Aug 28th, 2023 12:00 pm
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues
- Aug 16th, 2023 10:05 am
Scroll